Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
21.50
-0.10 (-0.46%)
Aug 12, 2025, 5:35 PM CET
-0.46%
Market Cap871.17M
Revenue (ttm)77.65M
Net Income (ttm)45.29M
Shares Out40.33M
EPS (ttm)1.12
PE Ratio19.29
Forward PE2.40
Dividendn/a
Ex-Dividend Daten/a
Volume4,902
Average Volume8,358
Open21.70
Previous Close21.60
Day's Range21.50 - 21.90
52-Week Range16.50 - 27.80
Beta0.14
RSI41.31
Earnings DateSep 23, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 183
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.